Company Profile

Avery Therapeutics Inc
Profile last edited on: 4/30/20      CAGE: 73GT3      UEI: EAEKFAHSBLQ1

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4425 Westflying Diamond Drive
Tucson, AZ 85742
   (928) 607-7410
Location: Single
Congr. District: 02

Public Profile

Avery Therapeutics is organized around advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle. ANchored in technology licensed fro University of Arizona, Tuscon, Avery’s first product, MyCardia™ is a tissue engineered graft for treatment of chronic heart failure. Chronic heart failure is a critical need worldwide with 26M people diagnosed and no therapies that effectively reverse the disease process or restore function to the heart long term. MyCardia™ has the potential to be the first available therapy that regenerates tissue and restores the heart to effective function for a high quality of life. MyCardia™ is a three part product comprised of a bio- absorbable scaffold seeded with fibroblasts and induced pluripotent stem cell derived cardiomyocytes. Each cell type provides a unique therapeutic element and taken together synergistically improves the heart better than other technologies. MyCardia™ mimics key molecular and cellular attributes of cardiac tissue and behaves like cardiac tissue. MyCardia™ beats spontaneously and synchronously and electrically couples with the heart. The firm's data showing that MyCardia™ improves cardiac function in pre-clinical models of heart failure and results in generation of new blood vessels and heart muscle. Pre-clinical studies with MyCardia™ have also shown improvements in diastolic function. Given that there are no existing therapies to treat diastolic dysfunction these results could potentially beo

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Steven Goldman -- Chief Medical Officer, Co-Founder

  Jen Watson Koevary -- Chief Operating Officer

  Jordan Lancaster -- Chief Scientific Officer, Co-Founder

Company News

There are no news available.